Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Latest filing published 09 May 2025 for Fulcrum Therapeutics, Inc., €2,245.
Filing timeline
BuySaleGreg Tourangeau
Insider track record
Disclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Greg Tourangeau: trading record in brief
All filings by Greg Tourangeau on record concern Fulcrum Therapeutics, Inc. In total, 5 filings cover trades dated from 6 May 2022 to 8 May 2025.
The open-market record consists of 4 sales worth €57k, with no purchase. Outside the open market, there are 1 share grant. So far in 2025, the count stands at no purchases and 1 sale.
The record was last updated on 9 May 2025 with an open-market sale (€2,245) in Fulcrum Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Greg Tourangeau
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
498 shares@ US$5.064.0% of flowCommon StockSEC:0000950170-25-068038:0
236 shares@ US$7.763.0% of flowCommon StockSEC:0000950170-24-056947:0
4,884 shares@ US$11.715591.9% of flowCommon StockSEC:0000950170-24-028827:0
210 shares@ US$3.311.1% of flowCommon StockSEC:0000950170-23-021245:0
3,250 shares0Common StockSEC:0000899243-22-017416:0
5 of 5 declarations
